Fennec Pharmaceuticals Inc. (FENC)
$
8.87
Key metrics
Financial statements
Free cash flow per share
-0.4224
Market cap
243.7 Million
Price to sales ratio
7.3185
Debt to equity
-2.5947
Current ratio
4.8483
Income quality
0.9752
Average inventory
1.8 Million
ROE
2.0045
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company, focusing on innovative solutions for unmet medical needs. The weighted average number of diluted shares outstanding is 27,294,000.00 reflecting potential dilution effects on shareholder value. The company's operating expenses amount to $41,786,000.00 encompassing various operational costs incurred in its pursuit of advancing clinical candidates. The gross profit ratio is 0.93 which illustrates the efficiency of the company’s production and sales operations. In its financial disclosures, Fennec Pharmaceuticals reported depreciation and amortization expenses of $1,032,000.00 reflecting the wear and tear of its assets. Furthermore, the company reported an income before tax of -$71,000.00 showcasing its pre-tax profitability and underlying operational strength. With its clinical stage product candidate, PEDMARK, a formulation of sodium thiosulfate aimed at preventing platinum-induced ototoxicity in pediatric cancer patients, Fennec is committed to improving treatment outcomes in vulnerable populations. As a small-cap player with a market capitalization of $243,720,076.00 Fennec Pharmaceuticals is well positioned in the biopharmaceutical sector, contributing significantly to the overall market landscape. The stock is affordable at $8.79 making it suitable for budget-conscious investors looking for opportunities in emerging companies. However, the stock has a low average trading volume of 68,904.00 indicating lower market activity which might affect liquidity. As it belongs to the Healthcare sector, Fennec Pharmaceuticals is driving innovation and growth, establishing itself as a key player in the Biotechnology industry, shaping the future of therapeutic solutions. Investors who focus on this sector may find valuable prospects as the company navigates its clinical development and market strategies.
Is Fennec Pharmaceuticals Inc. (FENC) a good investment?
Investing in Fennec Pharmaceuticals Inc. (FENC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Fennec Pharmaceuticals Inc. (FENC)'s stock forecast?
Analysts predict Fennec Pharmaceuticals Inc. stock to fluctuate between $3.96 (low) and $9.42 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Fennec Pharmaceuticals Inc.'s market capitalization?
As of 2025-08-29, Fennec Pharmaceuticals Inc.'s market cap is $243,720,076, based on 27,476,897 outstanding shares.
How does Fennec Pharmaceuticals Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Fennec Pharmaceuticals Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Fennec Pharmaceuticals Inc. (FENC) stock?
To buy Fennec Pharmaceuticals Inc. (FENC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for FENC. Place an order (Market, Limit, etc.).
What is the best time to invest in Fennec Pharmaceuticals Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Fennec Pharmaceuticals Inc. stock ever split?
Fennec Pharmaceuticals Inc.'s last stock split was 1:3 on 2014-09-09.
How did Fennec Pharmaceuticals Inc. perform in the last earnings report?
Revenue: $47,538,000 | EPS: -$0.02 | Growth: -97.33%.
Where can I find Fennec Pharmaceuticals Inc.'s investor relations reports?
Visit https://www.fennecpharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Fennec Pharmaceuticals Inc.?
You can explore historical data from here
What is the all-time high and low for Fennec Pharmaceuticals Inc. stock?
All-time high: $11.92 (2023-12-28) | All-time low: $3.82 (2021-12-01).
What are the key trends affecting Fennec Pharmaceuticals Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Jeffrey S. Hackman - CEO & Director Robert C.
globenewswire.com
~ Achieved Second Quarter 2025 Total Net Revenues of $9.7 Million ~ ~ Double Digit New Accounts in the Second Quarter of 2025, Including Notable Quarter-Over-Quarter Growth in Both Large Community Practices and Academic Centers, Supported by Targeted Sales Strategy and Enhanced Patient Support Services for PEDMARK ® ~ ~ Successful Initial Uptake of PEDMARQSI® in the United Kingdom and Germany with Additional EU Launches Planned ~ ~ Japan Clinical Trial (STS-J01) Results Expected in the Second Half of 2025 with Evaluation of Both Registration and Partnering or Licensing Expected Thereafter ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C.
globenewswire.com
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, August 14, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results.
zacks.com
Adherex Technologies (FENC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
globenewswire.com
RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 25, 2025 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held in New York, New York on June 3, 2025.
seekingalpha.com
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive Officer and Director Conference Call Participants Chase Knickerbocker - Craig Hallum Sudan Loganathan - Stevens Michael Okunewitch - Maxim Group Raghuram Selvaraju - H.C. Wainwright Operator Good morning, ladies and gentlemen.
globenewswire.com
RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results.
zacks.com
The average of price targets set by Wall Street analysts indicates a potential upside of 113.3% in Adherex Technologies (FENC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
zacks.com
The heavy selling pressure might have exhausted for Adherex Technologies (FENC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
seekingalpha.com
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q4 2024 Earnings Conference Call March 10, 2025 8:30 AM ET Company Participants Robert Andrade - CFO Jeff Hackman - CEO and Board Member Conference Call Participants Chase Knickerbocker - Craig-Hallum Raghuram Selvaraju - H.C. Wainwright Felix Ampomah - Stephens Michael Okunewitch - Maxim Group Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings and Corporate Update Conference Call.
See all news
